Eli Lilly & Co. closed $199.24 short of its 52-week high ($972.53), which the company achieved on August 22nd.

Eli Lilly's stock has been a strong winner over the past few years, powered by its portfolio of glucagon-like peptide-1 (GLP-1) receptor agonist drugs. The stock is up about 36% year to date as of this writing and has gained around 506% over the past five years.

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 484.89% and currently trading at $773.28. The company has been around since 1876 and the stock didn’t go public until 1952 but in the last 4 years,

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with unparalleled accuracy. Back To Top

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) benefit from innovative treatments for obesity and diabetes. Start Your Mornings Smarter! Wake up with Breakfast news in your inbox every market day.